PAVmed Inc. (PAVM)
- Previous Close
1.7400 - Open
1.7900 - Bid --
- Ask --
- Day's Range
1.7100 - 1.8600 - 52 Week Range
1.6000 - 9.0000 - Volume
30,329 - Avg. Volume
61,974 - Market Cap (intraday)
15.776M - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-9.1600 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.75
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
www.pavmed.comRecent News: PAVM
Performance Overview: PAVM
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PAVM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PAVM
Valuation Measures
Market Cap
15.78M
Enterprise Value
47.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.07
Price/Book (mrq)
--
Enterprise Value/Revenue
19.52
Enterprise Value/EBITDA
-0.63
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-98.73%
Return on Equity (ttm)
--
Revenue (ttm)
2.45M
Net Income Avi to Common (ttm)
-66.27M
Diluted EPS (ttm)
-9.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
22.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-27.92M